Fig. 2

CRISPR/Cas9-based therapy is targeted. A and B CCK-8 assay and cell apoptosis assay. Cells (293T; RD; A549; HEPG2; CasKi, HPV16 positive; 4T1) were treated with target-specific gRNA (E6E7) or control gRNA (non-specific), for 48 h before CCK-8 assay and cell apoptosis assay